The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)phenyl)-4-(dimethylamino)but-2-enamide ID: ALA4866812
PubChem CID: 134543415
Max Phase: Preclinical
Molecular Formula: C29H32ClN7O
Molecular Weight: 530.08
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CN(C)C/C=C/C(=O)Nc1ccc(N2CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1
Standard InChI: InChI=1S/C29H32ClN7O/c1-36(2)15-6-10-27(38)33-20-11-13-22(14-12-20)37-16-5-7-21(19-37)34-29-32-18-25(30)28(35-29)24-17-31-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,21,31H,5,7,15-16,19H2,1-2H3,(H,33,38)(H,32,34,35)/b10-6+/t21-/m1/s1
Standard InChI Key: VFUSOVNUCLAYBM-VMLCMGRWSA-N
Molfile:
RDKit 2D
38 42 0 0 0 0 0 0 0 0999 V2000
35.0732 -14.2391 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.0721 -15.0671 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.7874 -15.4802 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.5043 -15.0666 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5015 -14.2355 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.7855 -13.8261 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2199 -15.4783 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
37.9343 -15.0644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.6443 -15.4794 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.3564 -15.0690 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
39.3595 -14.2431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.6440 -13.8292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.9256 -14.2413 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.0705 -15.4834 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.3596 -15.4826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4649 -16.4747 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.2726 -16.3036 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.0527 -15.7593 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.6037 -15.1501 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3512 -14.3703 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.5480 -14.1987 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9979 -14.8129 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2532 -15.5903 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.3581 -13.8265 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
40.0652 -16.3084 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.7785 -16.7226 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.4954 -16.3114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.4946 -15.4815 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.7807 -15.0709 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.2099 -16.7249 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.9253 -16.3127 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.6399 -16.7261 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.9260 -15.4871 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.3552 -16.3139 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.0698 -16.7274 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.7852 -16.3152 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
46.4998 -16.7286 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.7859 -15.4896 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
4 7 1 0
8 7 1 6
8 9 1 0
8 13 1 0
9 10 1 0
10 11 1 0
11 12 1 0
12 13 1 0
10 14 1 0
15 19 1 0
18 16 1 0
16 17 1 0
17 15 2 0
2 15 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 18 1 0
1 24 1 0
14 25 2 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 14 1 0
27 30 1 0
30 31 1 0
31 32 1 0
31 33 2 0
32 34 2 0
34 35 1 0
35 36 1 0
36 37 1 0
36 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 530.08Molecular Weight (Monoisotopic): 529.2357AlogP: 5.42#Rotatable Bonds: 8Polar Surface Area: 89.18Molecular Species: BASEHBA: 6HBD: 3#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 8.81CX LogP: 5.12CX LogD: 3.70Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.26Np Likeness Score: -1.21
References 1. Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, Gray NS.. (2021) Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma., 221 [PMID:33945934 ] [10.1016/j.ejmech.2021.113481 ]